Join

Compare · BDX vs DXCM

BDX vs DXCM

Side-by-side comparison of Becton Dickinson and Company (BDX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BDX and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BDX is the larger of the two at $41.65B, about 1.5x DXCM ($28.11B).
  • Over the past year, BDX is down 13.4% and DXCM is down 10.5% - DXCM leads by 2.8 points.
  • DXCM has been more active in the news (26 items in the past 4 weeks vs 10 for BDX).
  • Both have 25 recent analyst ratings on file.
PerformanceBDX-13.38%DXCM-10.53%
2025-06-09+0.00%2026-06-08
MetricBDXDXCM
Company
Becton Dickinson and Company
DexCom Inc.
Price
$149.41-1.20%
$76.62+5.18%
Market cap
$41.65B
$28.11B
1M return
-2.49%
+25.75%
1Y return
-13.38%
-10.53%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
2005
News (4w)
10
26
Recent ratings
25
25
BDX

Becton Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Latest BDX

Latest DXCM